After oral administration, naproxen generates several side-effects related to stomach malfunction. Undoubtedly, the enteric dosage forms with naproxen can be considered as safer. Moreover, since it has been evidenced that development and growth of colorectal cancer is related to the presence of cyclooxygenase, naproxen is investigated in terms of the tumor prevention. The aim of the present work was to formulate and evaluate the properties of novel naproxen-loaded macrobeads, made on the basis of low-acyl gellan gum and its blends with carrageenans, guar gum, cellulose sulfate, and dextran sulfates.
Method
Seven formulations were prepared by ionotropic gelation. The morphology of the dried beads was evaluated by scanning electron microscopy. The next step focused on Raman spectroscopy and thermal analysis of naproxen, polymers, and the beads. Next, the swelling behavior was examined in three acceptor fluids at pH = 1.2; 4.5, and 7.4. The beads were evaluated regarding naproxen content and encapsulation efficiency. The last stage of the work concerned the drug release studies.
Results
Addition of any other polysaccharide than gellan resulted in flattening of the beads upon drying. Differential scanning calorimetry confirmed the crystalline form of naproxen. Raman spectra showed that no apparent interactions occurred. In the acidic environment, all the beads revealed the tendency to absorb water. The beads swelled to the greatest extent at pH = 4.5. Naproxen was released from the beads at a varied rate. At pH = 7.4, the most prolonged release was observed for the beads containing carrageenans.
Conclusions
We have proved that blending of gellan with various polysaccharides can change the pH-dependent properties of the beads loaded with naproxen. We believe that the information enclosed in the paper will be of particular importance regarding the development and characteristics of novel oral dosage forms based on natural polymers.
DugganKCWaltersMJMuseeJet al.
Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem2010;
285: 34950–34959.
2.
LaneuvilleOBreuerDKDewittDLet al.
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharm Exp Ther1994;
271: 927–934.
3.
CroffordLJ.COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl1997;
49: 15–19.
4.
BerryHSwinsonDJonesJet al.
Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. Ann Rheum Dis1978;
37: 370–372.
5.
BerryHBloomBHamiltonEBDet al.
Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain. Ann Rheum Dis1982;
41: 129–132.
6.
ThorlingJLindenBBergRet al.
A double-blind comparison of naproxen gel and placebo in the treatment of soft tissue injuries. Curr Med Res Opin1990;
12: 242–248.
7.
BertinPBéhierJMNoëlEet al.
Celecoxib is as efficacious as naproxen in the management of acute shoulder pain. J Int Med Res2003;
31: 102–112.
8.
MaccagnoADi GiorgioERomanowiczA.Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin1991;
12: 423–429.
9.
JohnsonESRatcliffeDMWilkinsonM.Naproxen sodium in the treatment of migraine. Cephalalgia1985;
5: 5–10.
10.
MilsomIHednerNMannheimerC.A comparative study of the effect of high-intensity transcutaneous nerve stimulation and oral naproxen on intrauterine pressure and menstrual pain in patients with primary dysmenorrhea. Am J Obstet Gynecol1994;
170: 123–129.
11.
LereimPGaborI.Piroxicam and naproxen in acute sports injuries. Am J Med1988;
84: 45–49.
12.
HalvorsenLDotevallGSeveliusH.Comparative effects of aspirin and naproxen on gastric mucosa. Scand J Rheumatol Suppl1973;
2: 43–47.
13.
ColesLSFriesJFKrainesRGet al.
From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med1983;
74: 820–828.
14.
GierckskyKEHusebyGRugstadHE.Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl1989;
163: 3–8.
15.
AabakkenLBjøirnbethBAHofstadBet al.
Comparison of the gastrointestinal side effects of naproxen formulated as plain tablets, enteric coated tablets, or enteric-coated granules in capsules. Scand J Gastroenterol Suppl1989;
163: 65–73.
16.
BombardierCLaineLReicinA.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med2000;
343: 1520–1528.
17.
SüleymanHDemircanBKaragözY.Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep2007;
59: 247–258.
18.
EberhartCECoffeyRJRadhikaAet al.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology1994;
107: ll83–1188.
19.
GuptaRADuboisRN.Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer2011;
1: 11–21.
20.
ShiffSJKoutsosMIQiaoLet al.
Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res1996;
222: 179–188.
21.
SanoHKawahitoYWilderRLet al.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res1995;
55: 3785–3789.
22.
BrownJRDuBoisRN.COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol2005;
23: 2840–2855.
23.
WangDDuBoisRN.The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene2010;
29: 781–788.
24.
SteeleVERaoCVZhangYet al.
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res Phila2009;
2: 951–956.
25.
BrogdenRNFinderRMSawyerPRet al.
Naproxen: a review of its pharmacological properties and therapeutic efficacy and use. Drugs1975;
9: 326–363.
26.
BrogdenRNHeelRCSpeightTMet al.
Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs1979;
18: 241–277.
27.
HardyGLamontGLEvansDFet al.
Evaluation of an enferic-coated naproxen pellet formulation. Aliment Pharmacol Thera1991;
5: 69–75.
28.
ŞanlıOSolakEK.Controlled release of naproxen from sodium alginate and poly(vinyl alcohol)/sodium alginate blend beads crosslinked with glutaraldehyde. J Appl Polym Sci2009;
112: 2057–2065.
29.
PiaoZZLeeMKLeeBJ.Colonic release and reduced intestinal tissue damage of coated tablets containing naproxen inclusion complex. Int J Pharm2008;
350: 205–211.
30.
AdibkiaKJavadzadehYDastmalchiSet al.
Naproxen-eudragit RS100 nanoparticles: preparation and physicochemical characterization. Colloids Surf B Biointerfaces2011;
83: 155–159.
31.
MaroniADel CurtoMDZemaLet al.
Film coatings for oral colon delivery. Int J Pharm2013;
457: 372–394.
32.
SmithAMInghamAGroverLMet al.
Polymer film formulations for the preparation of enteric pharmaceutical capsules. J Pharm Pharmacol2010;
62: 167–172.
33.
DeshmukhVNSinghSPSakarkarDM.Formulation and evaluation of sustained release metoprolol succinate tablet using hydrophilic gums as release modifiers. Int J PharmTech Res2009;
1: 159–163.
34.
FernándezHMJFellJT.Pectin/chitosan mixtures as coatings for colon-specific drug delivery: an in vitro evaluation. Int J Pharm1998;
169: 115–119.
35.
MilojevicSNewtonJMCummingsJHet al.
Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J Control Release1996;
38: 75–84.
36.
RubinsteinANakarDSintovA.Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery. Int J Pharm1992;
84: 141–150.
37.
PrezottiFGCuryBSFEvangelistaRC.Mucoadhesive beads of gellan gum/pectin intended to controlled delivery of drugs. Carbohydr Polym2014;
113: 286–295.
38.
OsmałekTFroelichATasarekS.Application of gellan gum in pharmacy and medicine. Int J Pharm2014;
466: 328–340.
39.
MaitiSRanjitSMondolRet al.
Al3+ ion crosslinked and acetalated gellan hydrogel network beads for prolonged release of glipizide. Carbohydr Polym2011;
85: 164–172.
40.
ČalijaBMilićJCekićNet al.
Chitosan oligosaccharide as prospective cross-linking agent for naproxen-loaded Ca-alginate microparticles with improved pH sensitivity. Drug Dev Ind Pharm2013;
39: 77–88.
41.
PengXZhuangQPengDet al.
Sustained release of naproxen in a new kind delivery system of carbon nanotubes hydrogel. Iran J Pharm Res2013;
12: 581–586.
42.
BishwambharMSuneethaV.Release study of naproxen, a modern drug from pH sensitive pullulan acetate microsphere. Int J Drug Dev Res2012;
4: 184–191.
43.
SolakEK.Preparation and characterization of IPN microspheres for controlled delivery of naproxen. J Biomater Nanobiotechnol2011;
2: 445–453.
44.
MahkamMPoorgholyN.Novel pH-sensitive carriers containing naproxen pendant groups for colon-specific drug delivery. Int J Polym Mater2011;
60: 1–10.
45.
RadhikaPRSaduBLakshmiPSet al.
Enteric coated beads of naproxen: design, development and evaluation. Int J PharmTech Res2012;
4: 1770–1776.
46.
CovielloTMatricardiPMarianecciCet al.
Polysaccharide hydrogels for modified release formulations. J Control Release2007;
119: 5–24.
47.
SinghBNTrombettaLDKimKH.Biodegradation behavior of gellan gum in simulated colonic media. Pharm Dev Technol2004;
9: 399–407.
48.
NampoothiriKMSinghaniaRRSabarinathCet al.
Fermentative production of gellan using Sphingomonas paucimobilis. Process Biochem2003;
45: 1513–1519.
GonçalvesVMReisADominguesMRMet al.
Structural analysis of gellans produced by Sphingomonas elodea strains by electrospray tandem mass spectrometry. Carbohydr Polym2009;
77: 10–19.
51.
GrasdalenHSmidsrødO.Gelation of gellan gum. Carbohydr Polym1987;
7: 371–393.
52.
MorrisERGothardMGEHemberMWNet al.
Conformational and rheological transitions of welan, rhamsan and acylated gellan. Carbohydr Polym1996;
30: 165–175.
53.
MorrisERNishinariKRinaudoM.Gelation of gellan – a review. Food Hydrocoll2012;
28: 373–411.
54.
NarkarMSherPPawarA.Stomach-specific controlled release gellan beads of acid-soluble drug prepared by ionotropic gelation method. AAPS PharmSciTech2010;
11: 267–277.
55.
AgnihotriSAJawalkarSSAminabhaviTM.Controlled release of cephalexin through gellan gum beads: effect of formulation parameters on entrapment efficiency, size, and drug release. Eur J Pharm Biopharm2006;
63: 249–261.
56.
SolankiHKPawarDDShahDAet al.
Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent. BioMed Res Int2013; 620719 Article ID
57.
ChandrasekaranRRadhaAThailambalVG.Roles of potassium ions, acetyl and L-glyceryl groups in native gellan double helix: an X-ray study. Carbohydr Res1992;
224: 1–17.
58.
SinghBNKimKH.Effects of divalent cations on drug encapsulation efficiency of deacylated gellan gum. J Microencapsul2005;
22: 761–771.
59.
QuigleyKJDeasyPB.Use of deacetylated gellan gum (Gelrite) for the production of sulphamethizole containing beads. J Microencapsul1992;
9: 1–7.
60.
KędzierewiczFLombryCRiosRet al.
Effect of the formulation on the in-vitro release of propranolol from gellan beads. Int J Pharm1999;
178: 129–136.
61.
OsmałekTFroelichAMilanowskiBet al.
pH-dependent behavior of novel gellan beads loaded with naproxen. Curr Drug Deliv2018;
15: 52–63.
62.
YangFXiaSTanC.Preparation and evaluation of chitosan-calcium-gellan gum beads for controlled release of protein. Eur Food Res Technol2013;
237: 467–479.
63.
CampoVLKawanoDLda SilvaDBet al.
Carrageenans: biological properties, chemical modifications and structural analysis – a review. Carbohydr Polym2009;
77: 167–180.
64.
LiLNiRShaoYet al.
Carrageenan and its applications in drug delivery. Carbohydr Polym2014;
103: 1–11.
MudgilDBarakSKhatkarBS.Guar gum: processing, properties and food applications – a review. J Food Sci Technol2014;
51: 409–418.
67.
MauckCFrezieresRWalshTet al.
Cellulose sulfate: tolerance and acceptability of penile application. Contraception2001;
64: 377–381.
68.
TaoWRichardsCHamerD.Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses2008;
24: 925–929.
69.
ZhuLYLinDQYaoS.Biodegradation of polyelectrolyte complex films composed of chitosan and sodium cellulose sulfate as the controllable release carrier. Carbohydr Polym2010;
82: 323–328.
70.
PuramaRKGoswamiPKhanATet al.
Structural analysis and properties of dextran produced by Leuconostoc mesenteroides NRRL B-640. Carbohydr Polym2009;
76: 30–35.
71.
AnithaADeepaganVGDivya-RaniVVet al.
Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate–chitosan nanoparticles. Carbohydr Polym2011;
84: 1158–1164.
72.
MitraSGaurUGhoshPet al.
Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Rel2001;
74: 317–323.
73.
NayakAKPalDSantraK.Tamarind seed polysaccharide gellan gum mucoadhesive beads for controlled release of metformin HCl. Carbohydr Polym2014;
103: 154–163.
74.
StatSoft, Inc. STATISTICA (data analysis software system), version 12, www.statsoft.com (2014; accessed 20 March 2018).
75.
PatilPChavankeDWaghM.A review on ionotropic gelation method: novel approach for controlled gastroretentive gelispheres. Int J Pharm Pharm Sci2012;
4: 27–32.
76.
Peres-FilhoMGaetiMPNde OliveiraSRet al.
Thermoanalytical investigation of olanzapine compatibility with excipients used in solid oral dosage forms. J Therm Anal Calorim2011;
104: 255–260.
77.
StulzerHKRodriguesPOCardosoTMet al.
Compatibility studies between captopril and pharmaceutical excipients used in tablets formulations. J Therm Anal Calorim2008;
91: 323–328.
78.
SkotnickiMAguilarJAPydaMet al.
Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry. Pharm Res2015;
32: 414–429.
BruniGBerbenniVMilaneseCet al.
Drug-excipient compatibility studies in binary and ternary mixtures by physico-chemical techniques. J Therm Anal Calorim2010;
102: 193–201.
81.
BharateSSBharateSSBajajAN.Incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excip Food Chem2010;
1: 3–26.
82.
WangYLuoYHZhaoJet al.
Selection of excipients for dispersible tablets of itraconazole through the application of thermal techniques and Raman spectroscopy. J Therm Anal Calorim2014;
115: 2391–2400.
83.
NortonSLacroixC.Gellan gum as an entrapment matrix for high temperature fermentation processes: a rheological study. Biotechnol Tech1990;
4: 351–356.
84.
Al-GousousJLangguthP.European versus United States pharmacopeia disintegration testing methods for enteric-coated soft gelatin capsules. Dissolution Technol2015;
22: 6–8.
